# DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

> **NCT00252863** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1600 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Symbicort, used twice daily (b.i.d) and as needed (prn)
- **DRUG:** Budesonide Turbuhaler 200 µg
- **DRUG:** Fluticasone Discus 250 µg
- **DRUG:** Formoterol Turbuhaler 4.5 µg
- **DRUG:** Terbutaline Turbuhaler 0.5 mg
- **DRUG:** Salbutamol pressurized metered dose inhaler (pMDI) 100 µg
- **DRUG:** Salmeterol Discus 50 µg
- **DRUG:** Budesonide/Formoterol Turbuhaler 160/4.5 µg
- **DRUG:** Fluticasone/Salmeterol Discus 250/50 µg
- **DRUG:** Fluticasone/Salmeterol Discus 500/50 µg
- **DRUG:** Theophylline 200 mg
- **DRUG:** Theophylline 300 mg
- **DRUG:** Singulair 10 mg

## Key facts

- **NCT ID:** NCT00252863
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 1600 (—)
- **Last updated:** 2009-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252863, "DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00252863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*